Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WELL Health Technologies Corp WHTCF


Primary Symbol: T.WELL Alternate Symbol(s):  T.WELL.DB

WELL Health Technologies Corp. is a practitioner-focused digital healthcare company. The Company develops technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. Its business units include Canadian Patient Services, WELL Health USA Patient Services and SaaS and Technology Services. WELL Health USA Patient and... see more

TSX:WELL - Post Discussion

WELL Health Technologies Corp > tip ranks - strong buy - average price target $9.32
View:
Post by speedy99 on Mar 22, 2023 9:56am

tip ranks - strong buy - average price target $9.32

WELL Health Stock (TSE:WELL) Soars on Strong Q4-2022 Earnings Results

Story Highlights

WELL Health’s earnings report and strong 2023 guidance were enough to send the stock higher today. WELL’s earnings matched expectations, while revenue came in higher than expected.

 

 

WELL Health Technologies (TSE:WELL), a healthcare services provider, recently reported record Q4 results (along with full-year 2022 results) that beat revenue expectations and matched earnings-per-share (EPS) estimates. The company also provided strong guidance for 2023. Mr.Market clearly likes the earnings report, as WELL stock is soaring.

 

 

Q4-2022 Results

 

 

In Q4 2022, WELL Health’s revenue rose to C$156.5 million (a 35% year-over-year increase), which beat expectations of C$153.57 million. Notably, its Virtual Services division saw growth of 74%, representing about 35% of the company’s revenue.

 

 

Also, WELL’s adjusted EPS came in at C$0.05, in line with the C$0.05 consensus estimate and last year’s figure of C$0.05.

 

 

Additionally, WELL Health’s adjusted EBITDA rose 6% year-over-year to C$27.2 million, but its adjusted gross profit margin decreased by 360 basis points to 51.3%.

 

 

Full-Year Results and 2023 Guidance

 

 

Moving on to full-year results, revenue grew by 88% to C$569 million, adjusted earnings per share were C$0.24 compared to C$0.09 in 2021, and adjusted EBITDA rose 73% to C$104.6 million. Moreover, cash flow from operations was C$76.55 million — a significant increase compared to C$22.27 million in the same period last year. Also, adjusted free cash flow was C$48.8 million.

 

 
 

 

Importantly, the company’s CFO mentioned that “in fiscal 2022, 96% of WELL’s $569.1M in revenues were either recurring or highly re-occurring in nature.”

 

 

Lastly, the company provided full-year 2023 guidance. Revenue is expected to land between C$665 million and C$685 million. Meanwhile, adjusted EBITDA is forecast to grow by 10%.

 

 

Is WELL Health Stock a Buy, According to Analysts?

 

 

Analysts are unanimously bullish on WELL stock, as it has three unanimous Buy ratings, making it a “Strong Buy.” The average WELL Health stock price target of C$9.32 implies about 104.8% upside potential.

 

 

 

 

Disclosure

 

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities